Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease

Journal of Neurology

Volumn 258, Issue 8, 2011, Pages 1393-1405

  Tsui, Alex ^a,b   Isacson, Ole ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Dyskinesias; Foetal grafting; Movement disorders; Neurotransplantation; Normal striatum; Parkinson's

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMPA RECEPTOR; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; DOPAMINE; DOPAMINE TRANSPORTER; DYNORPHIN; GLUTAMIC ACID; GROWTH FACTOR; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN DARPP 32; PREPROENKEPHALIN; REACTIVE OXYGEN METABOLITE; SEROTONIN;

A10 NEURON; A9 NEURON; AUTOREGULATION; BRAIN MITOCHONDRION; BRAIN TISSUE; BRAIN TRANSPLANTATION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL METABOLISM; CELL SUSPENSION; CLINICAL EFFECTIVENESS; CORPUS STRIATUM; DENERVATION; DEPOLARIZATION; DNA DAMAGE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENCEPHALITIS; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FETAL TISSUE TRANSPLANTATION; GENE INDUCTION; GRAFT SURVIVAL; HIBERNATION; HUMAN; IMMEDIATE EARLY GENE; MEDIUM SPINY NEURON; METABOLIC RATE; NERVE CELL; NERVE CELL EXCITABILITY; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVE POTENTIAL; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSPLANTATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PACEMAKER NERVE CELL; PARKINSON DISEASE; PATIENT SELECTION; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PUTAMEN; REVIEW; SEROTONINERGIC NERVE CELL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA; SURGICAL APPROACH; SYNAPSE; TREATMENT OUTCOME;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; DOPAMINE; FETAL TISSUE TRANSPLANTATION; HUMANS; NEURONS; PARKINSON DISEASE; SYNAPSES;

EID: 79961026686     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6061-6     Document Type: Review

References (77)

1. A Carlsson M Lindqvist T Magnusson 1957 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists Nature 180 4596 1200 13483658 10.1038/1801200a0 1:CAS:528:DyaG1cXis1Kjuw%3D%3D
2. W Matsuda T Furuta K Nakamura, et al. 2009 Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum J Neuroscience 29 2 444 453 10.1523/JNEUROSCI.4029-08.2009 1:CAS:528:DC%2BD1MXhtVKru74%3D
3. J Guzman JS Padilla C Savio Chan D James Surmeier 2009 Robust pacemaking in substantia nigra dopaminergic neurons J Neuroscience 29 35 11011 11019 10.1523/JNEUROSCI.2519-09.2009 1:CAS:528:DC%2BD1MXhtFehsLvJ
4. Paul Greengard's Nobel Lecture, Les Prix Nobel 2000
5. M Angela Cenci 2007 Dopamine dysregulation of movement control in l-dopa-induced dyskinesias Trends Neurosci 30 5 236 243 17400300 10.1016/j.tins.2007.03.005 (Pubitemid 46654236)
6. Nagatsu T, Sawada M (2009) l-dopa therapy for Parkinson's disease: past, present and future. Parkinsonism Relat Disord 15(S1):S3-S8
7. E Hirsch AM Graybiel YA Agid 1988 Melanized dopaminergic neurones are differentially susceptible to degeneration in Parkinson's disease Nature 334 345 348 2899295 10.1038/334345a0 1:CAS:528:DyaL1cXltVyms78%3D
8. DJ Surmeier 2007 Calcium, ageing, and neuronal vulnerability in Parkinson's disease Lancet Neurology 6 933 938 17884683 10.1016/S1474-4422(07) 70246-6 1:CAS:528:DC%2BD2sXht1Krtr%2FN (Pubitemid 47405004)
9. S Nedergaard JA Flatman I Engberg 1993 Nifedipine and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones J Physiol 466 727 747 8410714 1:CAS:528:DyaK3sXks1yqtrk%3D (Pubitemid 23225251)
10. CS Chan JN Guzman DJ Surmeier, et al. 2007 "Rejuvenation" protects neurons in mouse models of Parkinson's disease Nature 447 1081 1086 17558391 10.1038/nature05865 1:CAS:528:DC%2BD2sXmvFKmurY%3D (Pubitemid 47014425)
11. PA Garris EL Ciolkowski P Pastore RM Wightman 1994 Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain J Neurosci 14 6084 6093 7931564 1:CAS:528:DyaK2cXmsVKqt7o%3D (Pubitemid 24307800)
12. SR Jones RR Gainetdinov M Jaber Caron, et al. 1998 Profound neuronal plasticity in response to inactivation of the dopamine receptor Proc Natl Acad Sci USA 95 4029 4034 9520487 10.1073/pnas.95.7.4029 1:CAS:528:DyaK1cXitlKisrs%3D (Pubitemid 28173248)
13. D Herve M Rogard M Levi-Strauss 1995 Molecular analysis of the multiple Golf subunit mRNAs in the rat brain Brain Res Mole Brain Res 32 1 125 134 10.1016/0169-328X(95)00070-9 1:CAS:528:DyaK2MXmvVelsb8%3D
14. P Svenningsson A Nishi G Fisone P Greengard, et al. 2004 DARPP-32: an integrator of neurotransmission Annu Rev Pharmacol Toxicol 44 269 296 14744247 10.1146/annurev.pharmtox.44.101802.121415 1:CAS:528:DC%2BD2cXhvVCktLw%3D (Pubitemid 38263842)
15. KY Tseng P O'Connell 2004 Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms J Neurosci 24 5131 5139 15175382 10.1523/JNEUROSCI.1021-04.2004 1:CAS:528:DC%2BD2cXkvFOktrs%3D (Pubitemid 38728985)
16. DJ Surmeier J Ding W Shen, et al. 2007 D1 and D2 dopamine receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurones Trends Neurosci 30 5 228 235 17408758 10.1016/j.tins.2007.03.008 1:CAS:528:DC%2BD2sXkslent7o%3D (Pubitemid 46654239)
17. Snyder GL Allen Fienberg AA PB P Greengard, et al. 2000 Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo J Neurosci 20 4480 4488 10844017 (Pubitemid 30396613)
18. PJ Hallett R Spoelgen AW Dunah, et al. 2006 Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking J Neurosci 26 4690 4700 16641250 10.1523/JNEUROSCI.0792-06. 2006 1:CAS:528:DC%2BD28XksFWqu7w%3D (Pubitemid 44315370)
19. CR Gerfen 2003 Dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease The Neurosci 9 6 455 462 10.1177/1073858403255839 1:CAS:528:DC%2BD3sXhtVWnsL3K (Pubitemid 37467358)
20. A Pisani D Centonze G Bernardi P Calabresi 2005 Striatal synaptic plasticity: implications for motor learning and Parkinson's disease Mov Disord 20 4 395 402 15719415 10.1002/mds.20394 (Pubitemid 40779013)
21. R De la Fuente-Fernandez 2007 Presynaptic mechanisms of motor complications in Parkinson's disease Arch Neurol 64 141 142 10.1001/archneur.64. 1.141 (Pubitemid 46072439)
22. GS Robertson SR Vincent HC Fibiger 1990 Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos Brain Res 523 288 290 2144781 10.1016/0006-8993(90)91498-6 1:CAS:528:DyaK3cXltV2rt7k%3D (Pubitemid 20230158)
23. JD Berke RF Paletzki CR Gerfen, et al. 1998 A complex program of striatal gene expression induced by dopaminergic stimulation J Neurosci 18 5301 5310 9651213 1:CAS:528:DyaK1cXksFartrg%3D (Pubitemid 28311947)
24. S Impey K Obrietan DR Storm 1999 Making new connections: role of ERK. MAP kinase signaling in neuronal plasticity Neuron 23 1 11 14 10402188 10.1016/S0896-6273(00)80747-3 1:CAS:528:DyaK1MXjvVSjtLs%3D (Pubitemid 29262459)
25. CR Gerfen S Miyachi R Paletzi P Brown 2002 D1 dopamine receptor-supsensitivity in the dopamine-depleted striatum striatum results from a switch in the regulation of ERK1/2MAP kinase J Neurosci 22 5042 5054 12077200 1:CAS:528:DC%2BD38Xlt1SgsLk%3D (Pubitemid 37465618)
26. P Gubellini E Saulle D Centonze, et al. 2003 Corticostriatal LTP requires combined mGluR1 and mGluR5 activation Neuropharmacology 44 8 16 12559117 10.1016/S0028-3908(02)00214-9 1:CAS:528:DC%2BD3sXmsVentQ%3D%3D (Pubitemid 36135837)
27. D Centonze C Grande E Saulle, et al. 2003 Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity J Neurosci 23 8506 8512 13679419 1:CAS:528:DC%2BD3sXns1SrsL8%3D (Pubitemid 37158750)
28. B Picconi D Centonze K Hakansson, et al. 2003 Loss of bidirectional striatal synaptic plasticity in l-dopa induced dyskinesias Nat Neurosci 6 501 506 12665799 1:CAS:528:DC%2BD3sXjtFKnsLo%3D (Pubitemid 36514698)
29. P Gubellini E Saulle D Centonze, et al. 2001 Selective involvement of mGlu1 receptors in corticostriatal LTD Neuropharmacologu 40 839 846 10.1016/S0028-3908(01)00021-1 1:CAS:528:DC%2BD3MXjvV2gtbo%3D (Pubitemid 32510797)
30. N Lindefors U Ungerstedt 1990 Bilateral regulation of glutamate tissue and extracellular levels in the caudate-putamen by midbrain dopamine neurons Neurosci Lett 115 248 252 1978265 10.1016/0304-3940(90)90463-J 1:CAS:528:DyaK3cXlsVGkurg%3D (Pubitemid 20231622)
31. P Anglade A Mouatt-Prigent Y Agid, et al. 1996 Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease Neurodegeneration 5 121 128 8819132 10.1006/neur.1996.0018 1:STN:280:DyaK28vhs1ahtA%3D%3D (Pubitemid 26248601)
32. R De la Fuente-Fernandez M Schulzer E Mak DB Calne AJ Stoessl 2004 Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model Brain 127 P4 888 899 10.1093/brain/awh102 (Pubitemid 38478533)
33. M Carta T Carlsson D Kirik A Bjorklund 2007 Dopamine release from 5-HT terminals is the cause of l-dopa induced dyskinesias in Parkinsonia rats Brain 130 1819 1833 17452372 10.1093/brain/awm082 (Pubitemid 47343795)
34. H Tanaka K Kannari T Maeda M Tomiyama T Suda M Matsunaga 1999 Role of serotonergic neurons in l-dopa-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 631 634 10208602 10.1097/00001756- 199902250-00034 1:CAS:528:DyaK1MXisFantL0%3D (Pubitemid 29333295)
35. M Politis K Wu C Loane P Piccini, et al. 2010 Serotonergic neurones mediate dyskinesias side effects in Parkinson's patients with neural transplants Sci Transl Med 2 38 38 46
36. K Hakansson M Lindskog L Pozzi, et al. 2004 DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia Parkinsonism Relat Disord 10 281 286 15196506 10.1016/j.parkreldis.2004.02.010 (Pubitemid 38757808)
37. B Picconi F Gardoni D Centonze, et al. 2004 Abnormal Ca2-calmodulin- dependent protein kinase II function mediates synaptic and motor deficits in experimental Parkinsonism J Neurosci 24 5283 5291 15190099 10.1523/JNEUROSCI. 1224-04.2004 1:CAS:528:DC%2BD2cXltFCgtb0%3D (Pubitemid 38747668)
38. M Sheng MJ Kim 2002 Postsynaptic signaling and plasticity mechanisms Science 298 776 780 12399578 10.1126/science.1075333 1:CAS:528: DC%2BD38XotFSnur4%3D (Pubitemid 35231521)
39. M Morissette R Grondin M Goulet PJ Bedard T Di Paolo 1999 Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists J Neurochem 72 682 692 9930741 10.1046/j.1471-4159.1999.0720682.x 1:CAS:528:DyaK1MXmt1ymsg%3D%3D (Pubitemid 29055231)
40. F Calon S Birdi AH Rajput O Hornykiewicz PJ Bedard T Di Paolo 2002 Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias J Neuropathol Exp Neurol 61 186 196 11853020 1:CAS:528:DC%2BD38XitFOku7c%3D (Pubitemid 34127102)
41. P Piccini RA Weeks DJ Brooks 1997 Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias Ann Neurol 42 720 726 9392571 10.1002/ana.410420508 1:STN:280:DyaK1c%2Flt1Cltg%3D%3D (Pubitemid 27481544)
42. B Henry SH Fox AR Crossman JM Brotchie 2001 Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Exp Neurol 171 139 146 11520128 10.1006/exnr.2001.7727 1:CAS:528:DC%2BD3MXmtFyqtrk%3D (Pubitemid 32848452)
43. F Calon T Di Paolo 2002 Levodopa response complications-GABA receptors and preproenkephalin expression in the human brain Parkinsonism Relat Disord 8 449 454 12217634 10.1016/S1353-8020(02)00029-9 (Pubitemid 36151662)
44. A Vinuela PJ Hallett O Isacson, et al. 2008 Implanted reuptake-deficient or wild-type dopaminergic neurons improve on l-dopa dyskinesias without off-dyskinesias in a rat model of Parkinson's disease Brain 131 3361 3379 18988638 10.1093/brain/awn192 1:STN:280:DC%2BD1M%2Fgtlersw%3D%3D
45. K Wictorin P Brundin B Gustavii O Lindvall A Bjorklund 1990 Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts Nature 347 556 558 1699131 10.1038/347556a0 1:STN:280: DyaK3M%2FhsFemuw%3D%3D (Pubitemid 20341545)
46. O Isacson T Deacon P Pakzaban W Galpern J Dinsmore L Burns 1995 Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres Nat Med 1 11 1189 1194 7584993 10.1038/nm1195-1189 1:CAS:528:DyaK2MXptFahsL8%3D
47. O Isacson T Deacon 1996 Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat Neuroscience 75 3 827 837 8951876 10.1016/0306-4522(96)00305-3 1:CAS:528:DyaK28XnsVSqsbc%3D (Pubitemid 26377052)
48. CR Freed RE Breeze NL Rosenberg, et al. 1992 Survival of implanted foetal dopaminergic cells and neurologic improvement 12-46 months after transplantation for Parkinson's disease NEJM 327 22 1549 1555 1435881 10.1056/NEJM199211263272202 1:STN:280:DyaK3s%2FmtlSltw%3D%3D
49. Cooper O (2010) Neuroregeneration Laboratories, Harvard University. Personal communication
50. O Isacson LM Bjorklund JM Schumacher 2003 Towards full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease from regeneration and neuronal replacement by stem cell Ann Neurol 53 135 148 10.1002/ana.10482 (Pubitemid 36368569)
51. SL Maxwell HY Ho E Kuehner S Zhao M Li 2005 Pitx-3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development Dev Biol 282 467 479 15950611 10.1016/j.ydbio.2005.03.028 1:CAS:528:DC%2BD2MXltFSqs7o%3D (Pubitemid 40799336)
52. S Grealish M Jonsson M Li D Kirik A Bjorklund L Thompson 2009 The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease Brain 133 482 495 10.1093/brain/awp328
53. D Kirik C Winkler A Bjorklund 2001 Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration J Neurosci 21 2889 2896 11306640 1:CAS:528:DC%2BD3MXjtVWrs7g%3D (Pubitemid 32298229)
54. CR Freed PE Greene RE Breeze S Fahn, et al. 2001 Transplantation of embryonic dopamine neurons for severe Parkinson's disease NEJM 344 10 710 719 11236774 10.1056/NEJM200103083441002 1:STN:280:DC%2BD3M7ltFCisQ%3D%3D (Pubitemid 32204988)
55. JW Fawcett RA Barker SB Dunnett 1995 Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon Exp Brain Res 106 275 282 8566192 10.1007/BF00241123 1:CAS:528:DyaK2MXpvF2hsrc%3D
56. H Braak K Del Tredici 2008 Assessing fetal nerve cell grafts in Parkinson's disease Nat Med 14 483 485 18463652 10.1038/nm0508-483 1:CAS:528:DC%2BD1cXlsFCnu74%3D (Pubitemid 351655198)
57. CW Olanow CG Goetz JH Kordower, et al. 2003 A double-blind controlled trial of bilateral foetal nigral transplantation in Parkinson's disease Ann Neurol 54 403 414 12953276 10.1002/ana.10720 (Pubitemid 37072046)
58. P Piccini N Pavese P Hagell J Reimer A Bjoörklund WH Oertel, et al. 2005 Factors affecting the clinical outcome after neural transplantation in Parkinson's disease Brain 128 2977 2986 16246865 10.1093/brain/awh649 (Pubitemid 41746650)
59. JH Kordower Y Chu RA Hauser TB Freeman CW Olanow 2008 Lewy body like pathology in long-term embryonic nigral transplants in Parkinson's disease Nat Med 14 5 504 506 18391962 10.1038/nm1747 1:CAS:528:DC%2BD1cXlsFCmsrg%3D (Pubitemid 351655212)
60. I Mendez A Vinuela A Astradsson K Mukhida P Hallett O Isacson, et al. 2008 Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years Nat Med 14 5 483 485 10.1038/nm1752 (Pubitemid 351655215)
61. C Geny S Naimi-Sadaoui R Jeny AM Belkadi SL Juliano M Peschanski 1994 Long-term delayed vascularisation of human neural transplants to the rat brain J Neuroscience 14 7553 7562 1:CAS:528:DyaK2MXis1emu7w%3D (Pubitemid 24379763)
62. P Jenner 2003 Oxidative stress in Parkinson's disease Ann Neurol 53 S3 S26 S38 12666096 10.1002/ana.10483 1:CAS:528:DC%2BD3sXjtFGitLs%3D (Pubitemid 36368560)
63. O Cooper A Astradsson P Hallett H Robertson I Mendez O Isacson 2009 Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients J Neurol 356 S3 S310 S316 10.1007/s00415-009-5242-z
64. DE Redmond Jr A Vinuela JH Kordower O Isacson 2008 Influence of cell preparation and target location on the behavioural recovery after striatal transplantation of foetal dopaminergic neurons in a primate model of Parkinson's disease Neurobiol Dis 29 103 116 17920901 10.1016/j.nbd.2007.08.008 1:CAS:528:DC%2BD2sXhsVSns7bL (Pubitemid 350186113)
65. O Isacson 2003 The production and use of cells as therapeutic agents in neurodegenerative diseases Lancet Neurol 2 417 424 12849120 10.1016/S1474- 4422(03)00437-X 1:CAS:528:DC%2BD3sXms1yhsLc%3D (Pubitemid 36793934)
66. Y Ma C Tang T Chaly P Greene R Breeze S Fahn C Freed V Dhawan D Eidelberg 2010 Dopamine cell implantation in Parkinson's disease: long-term clinical and 18F-Fdopa PET outcomes J Nucl Med 52 7 15 10.2967/jnumed.109.066811
67. I Mendez R Sanchez-Pernaute O Cooper A Vinuela D Ferrari L Bjorklund A Dagher O Isacon 2005 Cell type analysis of functional foetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease Brain 128 1498 1510 15872020 10.1093/brain/awh510 (Pubitemid 41373670)
68. JY Li E Englund J Holton D Soulet P Hagell A Lees O Lindvall P Brundin 2008 Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation Nat Med 14 5 501 503 18391963 10.1038/nm1746 1:CAS:528:DC%2BD1cXlsFCmsrs%3D (Pubitemid 351655211)
69. JT Greenamyer TG Hastings 2004 Parkinson's-divergent causes, convergent mechanisms Science 304 1120 1122 10.1126/science.1098966 (Pubitemid 38661838)
70. P Piccini D Brooks A Bjorklund O Lindvall, et al. 1999 Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient Nat Neurosci 2 12 1137 1140 10570493 10.1038/16060 1:CAS:528:DyaK1MXnslKqtLk%3D (Pubitemid 30126374)
71. AC Bostan PL Strick 2010 The cerebellum and basal ganglia are interconnected Neuropsychol Rev 20 261 270 20811947 10.1007/s11065-010-9143-9
72. AE Kingsbury R Bandopadhyay L Silvera-Moriyama AJ Lees 2010 Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model Mov Disord 25 15 2508 2515 20818670 10.1002/mds.23305
73. PA Pahapill AM Lozano 2000 The pedunculopontine nucleus and Parkinson's disease Brain 123 pt9 1767 1783 10960043 10.1093/brain/123.9.1767 (Pubitemid 30664282)
74. PT Francis EK Parry 2007 Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies Mov Disord 22 S17 351 357 10.1002/mds.21683 (Pubitemid 350134188)
75. G Natale L Pasquali S Ruggieri A Paparelli F Fornai 2008 Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation Neurogastenterol Motil 20 741 749 10.1111/j.1365-2982.2008. 01162.x 1:CAS:528:DC%2BD1cXovFSnu7s%3D (Pubitemid 351814395)
76. TG Beach CH Adler LI Sue, et al. 2010 Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders Acta Neuropathol 119 689 702 20306269 10.1007/s00401-010-0664-3 1:CAS:528:DC%2BC3cXlslWgtL0%3D
77. MU Ferraye B Debu V Fraix P Pollak, et al. 2010 Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease Brain 133 pt1 205 214 19773356 10.1093/brain/awp229 1:STN:280: DC%2BC3c%2FgsVeksQ%3D%3D